A new study underway at St. David’s Surgical Hospital could help men recover faster and live a better quality of life after ...

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...

Fresh from a European cancer conference that was all about antibody-drug conjugates (ADCs), GSK has turned to French biotech ...

The National Institute for Health and Care Excellence (NICE) has recommended darolutamide in combination with androgen ...

NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...

GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia in a ...

GSK shares lifted on Monday after the pharmaceutical giant signed a £268m deal with French biotech Syndivia for a potential treatment for prostate cancer.

Nearly three years clean and having massively turned his life around, Jack Curran tells LADbible about the 'life-long' ...

Gerhardt Attard, M.D., Ph.D., from University College London, and colleagues conducted a double-blind trial that evaluated combining niraparib with AAP versus placebo and AAP in mCSPC with HRR gene ...

And far from going out of style, surveys suggest we're eating more tinned foods than ever before. Half of all Britons have up ...

(Alliance News) - GSK PLC on Monday announced an agreement with Syndivia that grants GSK exclusive worldwide rights to develop and commercialise a preclinical antibody-drug conjugate for metastatic ...